Background. Antiviral-resistant herpes simplex virus type 1 (HSV-1) has been recognized as an emerging clinical problem among patients undergoing hematopoietic stem cell transplantation (HSCT).
Because the reactivation of latent herpes simplex virus type 1 (HSV-1) is a cause of chronic and intractable herpetic lesions in patients who undergo hematopoietic stem cell transplantation (HSCT), the administration of prophylactic acyclovir (ACV) has become routine clinical practice during HSCT and has reduced the incidence of severe HSV-1 disease [1] [2] [3] . Still, the frequent emergence of ACV-resistant (ACVr) HSV-1 [4] [5] [6] and ACVr HSV-1 infections among HSCT patients have been suggested to have a considerable impact [7, 8] . However, the full picture of ACVr HSV-1 infections in HSCT patients remains unclear because there have been no prospective cohort studies on this issue.
Herpes simplex virus type 1 exhibits resistance to ACV due to mutations in viral thymidine kinase (vTK) and/or DNA polymerase (DNA-pol) genes. In general, the ACV resistance of HSV-1 is reported to be attributable to the former and latter causes in 95% and 5% of the cases, respectively [9] [10] [11] . However, knowledge of the viral genetic background of ACV resistance in HSCT patients remains limited.
A 2-year prospective surveillance study on the reactivation of HSV-1 and the emergence of ACVr HSV-1 during HSCT was conducted. The association between HSV-1 shedding and the prognosis of HSCT patients was evaluated. Moreover, various ACV resistance-associated mutations in the vTK and DNA-pol genes, including several novel mutations, were also determined. This study may shed light on some aspect of HSV-1 infections in HSCT patients. according to the previously described criteria [12] . A typical conditioning regimen included a combination of variable doses of fludarabine, busulfan, melphalan, and/or total body irradiation. Conditioning regimens that included >8 mg/kg of busulfan or >6 Gy of total body irradiation were defined as myeloablative conditioning regimens; other regimens were described as reduced intensity conditioning regimens [13] . Tacrolimus or cyclosporin A with or without mycophenolate motifil or short-term methotrexate was administered as a prophylactic therapy against graftversus-host disease (GVHD) in patients who received human leukocyte antigen (HLA)-mismatched transplants. Acute GVHD was classified according to the consensus criteria. The HSV-1 serostatus was not routinely examined before HSCT based on the assumption that almost all of the patients enrolled in this study had latent HSV-1, considering the high seroprevalence of HSV-1 in the Japanese adult population [14, 15] . All of the patients received ACV (600 mg/d, orally) as prophylaxis until at least 1 year after transplantation. The ethical review boards of Toranomon Hospital, National Sendai Medical Center, and the National Institute of Infectious Diseases approved the study. Written informed consent was obtained from each patient, and the study adhered to the tenets of the Declaration of Helsinki.
Sample Collection, Virus Isolation, and Identification
Oropharyngeal (OP) swabs were obtained once per week from each patient, regardless of their symptoms. The samples were collected from day −7 to day 100 of HSCT or until the day of discharge from the hospital (the day of HSCT was defined as day 0) (Figure 1 ). The OP samples were immediately stored at 4°C and were sent to the Virus Research Center, Sendai Medical Center. Virus isolation and identification were carried out by previously described methods [16, 17] . The harvested viruses were deep-frozen and sent to the National Institute of Infectious Diseases, where they were grown in Vero cells with Eagle's minimum essential medium containing 2% fetal bovine serum and used (within 2 passages) for further analyses.
Sensitivity Assay by Plaque Reduction Assay
The sensitivity of all of the HSV-1 isolates to ACV was evaluated with a plaque reduction assay (PRA) in Vero cells as described previously [18] . The isolates, to which the 50% inhibitory concentration (IC 50 ) of ACV (ACV-IC 50 ) showed values of >2 μg/ mL on a PRA, were considered to be ACVr. When sequential isolates were obtained from a single patient, a >5-fold increase in the ACV-IC 50 values was also considered to indicate the emergence of ACV resistance, according to the standard [11] . The sensitivity of the representative ACVr HSV-1 isolates to ganciclovir (GCV) and foscarnet (FOS) was also tested with a PRA. The isolates with an FOS-IC 50 of >100 μg/ml were considered to be resistant to FOS [19] . Those with a GCV-IC 50 value of >5 times that of ACV-sensitive (ACVs) HSV-1 TAS were defined as GCV resistant in this study. Viral thymidine kinase-positive HSV-1 TAS and vTK-negative HSV-1 TAR strains were used as the reference strains for the ACVs and ACVr strains, respectively [20] . Antiviral compound, ACV, GCV, and FOS were used for the PRAs. The ACV sensitivity of the isolates was preliminarily determined in a timely manner by PRA.
Genetic Analysis
To investigate the genetic mutations of the ACVr isolates, the nucleotide sequences of the vTK and/or DNA-pol genes were determined according to a previously described method [20] . First, the genetic sequence of the vTK gene was analyzed. When no mutations responsible for resistance were determined in the vTK gene, a sequence analysis of the DNA-pol gene was performed.
When a novel mutation in the vTK was found in the ACVr isolates, a functional analysis was performed, according to a previously described method to investigate the vTK gene mutations that were not known to be relevant to ACV resistance, as described below briefly [21] . 293T cells (human embryo kidney cells with the T-antigen expression) were used. Viral thymidine kinase-positive and ACV-sensitive (ACVs) HSV-1 TAS and vTK-negative and highly ACVr HSV-1 TAR were used as the reference ACVs and ACVr strains, respectively [20, 21] . The recombinant vTK with the mutation was expressed in 293T cells by transfection with the expression vector to indirectly evaluate the ACV phosphorylation activity of the vTK mutants of interest. The brief procedure of the assay was as follows. Full-length vTK gene with the mutation to be tested was amplified from each of the HSV-1 isolates and was cloned into the cloning site of the expression vector, pTARGET. 293T cells were then transfected with the expression vector plasmid and Figure 1 . The oropharyngeal (OP) sample collection schedule and treatments for all patients. The day on which transplantation was carried out was defined as day 0. The OP samples were collected weekly from day −7 until day 100. Patients were administered with acyclovir (ACV) for prophylaxis. All patients were also administered with immunosuppressive agents for graft-versus-host disease (GVHD) prophylaxis. They were treated for other specific infectious diseases such as bacterial and fungal infections including cytomegalovirus diseases, which occurred as complications, as necessary. Abbreviations: ATG, anti-thymocyte globulin; MAC, myeloablative conditioning; RIC, reduced intensity conditioning. incubated for 2 days. 293T cells were independently transfected with pTARGET, which was inserted with the full-length vTK gene of HSV-1 TAS or with the empty pTARGET, as positive and negative controls, respectively. After the incubation time, these cells were infected with HSV-1 TAR and were incubated in medium containing ACV at concentrations of 0, 0.4, 4, and 40 μg/mL for 24 hours. After the freezing and thawing of these cells, which were cultured at designated concentration of ACV, the infectious dose of HSV-1 TAR was determined by PFA. The inhibitory effects of ACV on the replication of HSV-1 TAR in the 293T cells expressed with each vTK mutant, vTK (TAS strain), and vTK nonexpressing cells were evaluated by standardization. The standardization method has been reported previously [21] . When this assay was performed, the expression of each recombinant vTK was confirmed to be the same level by Western blotting [21] .
Statistical Analysis
A two-sided Fisher's exact test using 2 × 2 tables was performed to compare the clinical characteristics of the patients with and without ACVr HSV-1 shedding. The Mann-Whitney U test was used to compare continuous variables such as age and days from HSCT to engraftment of transplanted stem cells. Cox proportional hazard regression with time-dependent covariates was performed for analyzing the association of HSV-1 isolation positive with the prognosis in the patients. Univariate and multivariate Cox regression models were applied to analyze the risk factors for ACVr HSV-1 shedding. Factors with P < .2 in the univariate analysis were included in a stepwise multivariate analysis. P < .05 was considered to indicate statistical significance. All of the analyses were conducted using JMP 11 software program, except for Cox proportional hazard model with time-dependent covariates, which was conducted by EZR, a graphical user interface for R [22] .
RESULTS

Patients
During the study period, 269 consecutive HSCTs were carried out for 251 patients; these included 26 retransplantations in 24 patients. Almost all patients had a history of ACV administration before entering this study, when they had been treated for the underlying disease with chemotherapeutic drugs or when they had undergone HSCT. Eight of the 26 retransplants were conducted within 100 days of the previous HSCT due to graft failure (n = 5) or relapse (n = 3). Each retransplant was considered to be part of a single HSCT session. The remaining 18 retransplants were conducted >100 days after the previous transplant. Thus, these 18 retransplants were regarded as independent HSCT procedures. One patient was transferred to another hospital within 100 days and was therefore excluded from the analysis. Consequently, the data of 268 HSCTs in 250 patients were analyzed. Overall, 2747 OP samples (mean = 10.3 per transplantation) were collected.
Herpes Simplex Virus Type 1 Isolation
One hundred three OP samples (3.7%) were positive for HSV-1 isolation. Thirty-five of the 103 HSV-1 isolates (34%) were ACVr. Herpes simplex virus type 2 was not isolated from any patients. Although various respiratory viruses (parainfluenza, influenza, adenovirus, and others; data not shown) were also isolated, they were not investigated in this study, , in which only HSV-1 infections were focused.
The Incidence of Herpes Simplex Virus Type 1 Shedding and the
Emergence of Ayclovir-Resistant Herpes Simplex Virus Type 1
The clinical characteristics, including the underlying diseases and the stem cell sources of each group (HSV-1 shedding negative, only ACVs HSV-1 shedding positive, and ACVr HSV-1 shedding positive), are shown in Table 1 . Herpes simplex virus type 1 was isolated in 39 of 268 HSCTs (15%). Acyclovirresistant HSV-1 emerged in 11 of 39 patients with HSV-1 shedding (28%). When HSV-1 was isolated from patients, no patients showed HSV-1-specific diseases of herpes labialis or periocular herpetic lesions. When HSV-1 was isolated from these patients, some suffered from stomatitis. However, there was no evidence that the stomatitis was caused by HSV-1. No patients died as a direct result of HSV-1 disease. Death occurred within 100 days of HSCT in 89 of 268 patients, mostly because of infection, followed by treatment-related complications and relapses.
The Risk Factors for Acquiring Acyclovir-Resistant Herpes Simplex Virus Type 1 Shedding and its Impact on the Survival Rate
The ACVr HSV-1-positive patient group was characterized by a high frequency of underlying relapsed malignant diseases and the use of reduced intensity conditioning ( Table 2 ). Seven of the 11 patients died within 100 days after HSCT; death was attributable to infections other than HSV-1 (n = 4) or treatment-related complications (n = 3). A high mortality rate was noticed among the patients positive for HSV-1 shedding.
Cox proportional hazard regression analysis with time-dependent covariates was performed for the assessment of the impact of HSV-1 shedding regardless of ACV sensitivity (n = 39) and of ACVr HSV-1 shedding (n = 11) on the prognosis of the patients. Because the software used for the analysis was only able to specify 1 covariate as the time-dependent one, the computation was done independently for analysis of either HSV-1 shedding or ACVr HSV-1 shedding as the covariate versus those without HSV-1 shedding. When the impact of HSV-1 shedding was analyzed, HSV-1 shedding-positive patients had a significantly higher hazard ratio than those without HSV-1 shedding (hazard ratio [HR] = 2.44; 95% confidence interval [CI] = 1.35-4.39; P = .003). When the impact of ACVr HSV-1 shedding was analyzed, ACVr HSV-1 shedding-positive patients had a significantly higher hazard ratio (HR = 2.93; 95% CI = 1.15-7.47; P = .03).
The risk factors for the emergence of ACVr HSV-1 are summarized in Table 3 . Among the factors that were analyzed, HSCT for relapsed malignant disease was found to be a statistically significant risk factor for the emergence of ACVr HSV-1 by both the univariate and multivariate analyses. 
The Phenotypic and Genotypic Analyses of the Acyclovir-Resistant Herpes Simplex Virus Type 1 Isolates
The phenotypic and genotypic features of the 52 HSV-1 isolates, including the 35 ACVr strains, from these 11 patients are shown in Table 4 . DNA-pol-associated ACVr mutants were isolated in 5 patients (45%), and vTK-associated ACVr mutants were isolated in 6 patients (55%). By aligning the DNA sequences with those deposited in the GenBank database, 2 novel vTK mutations (L327R [patient no. 118] and G56D [patient no. 185]), and 1 DNA-pol mutation (I890M [patient no. 23]) were identified as being responsible for conferring ACV resistance. Among these mutations, it could not be confirmed whether an L327R mutation in vTK (patient no. 118) conferred ACV resistance because all of the HSV-1 isolates from this patient harbored the same mutation. The mutation, vTK-L327R, and other vTK missense mutations were assessed to determine whether these mutations conferred ACV resistance. In accordance with the genotype-phenotype comparison in Table 4 , the resistance-conferring effects of the E95St, G200D (patient no. 206), G56D (patient no. 185), and Q342St (patient no. 136) mutations were confirmed, and it was shown that the G279D (patient no. 185) mutation did not confer ACV resistance (Figure 2 ). Regarding the other antiviral compounds, most vTK-associated ACVr HSV-1 strains were cross-resistant to GCV, whereas DNA-pol-associated ACVr isolates were sensitive to GCV (Table 4) . Four of the 5 DNA-pol-associated ACVr HSV-1 genotypes displayed cross-resistance to FOS.
DISCUSSION
The prevalence of ACVr HSV-1 is not reported to have increased in immunocompetent patients [23] [24] [25] , whereas ACVr HSV-1 is reported to be highly prevalent in HSCT patients [7, 8, 11, 26] . However, the full picture of HSV-1 infections, including the subclinical shedding of ACVr HSV-1 in HSCT patients, has remained unclear because studies have not been conducted in a prospective manner. This study was unique because it included a relatively large number of patients and was prospective in nature.
The breakthrough reactivation of HSV-1 was demonstrated to occur in approximately 15% of HSCT patients receiving ACV prophylaxis within 100 days after transplantation. Because all of the patients in this cohort were hospitalized and were expected to have had an extremely small chance of acquiring primary or super HSV-1 infections, all of the HSV-1 isolates were considered to have occurred due to reactivation; however, we did not evaluate the baseline serostatus of the patient. In this study, 600 mg/day of ACV was prescribed to the patients prophylactically for the prevention of HSV and varicella-zoster virus infections, although 800 mg of ACV twice daily is recommended for prophylactic use [27] . There is no evidence that the lower dose of ACV prophylaxis in this study did not protect the patients from HSV-1 reactivation, and that the standard dose (800 mg of ACV twice daily)-based ACV prophylactic use could protect the HSCT patients from HSV-1 reactivation. However, the possibility that the lower dose of ACV prophylaxis was associated with the high level of HSV-1 reactivation (39 of 268 HSCTs [15%]) can not be excluded. Further study is needed to address this issue.
To the best of our knowledge, this is the first prospective study to show the possible association of HSV-1, including both ACVs and ACVr HSV-1, shedding with a poorer outcome in HSCT patients and vice versa. A few previous retrospective reports demonstrated a relationship between the reactivation of HSV-1 and the long-term outcomes of HSCT patients; however, these studies did not investigate ACV resistance [28, 29] . The relationship between ACVr HSV-1 shedding and poorer outcomes in HSCT patients was only suggested in one recent case-control study [30] , which was concordant with our results. However, we could not claim that the emergence of ACVr HSV-1 was itself a life-threatening event in HSCT patients because none of the patients with ACVr HSV-1 shedding showed HSV-1-specific disease and had fatal HSV-1 disease in this 2-year prospective study. We further analyzed the patients' clinical backgrounds to identify the differences between the patents with ACVr HSV-1 shedding and those without. The relapse of malignant disease was found to be a significant risk factor for ACVr HSV-1 shedding. This result was quite convincing because patients with relapsed malignancies generally have longer disease histories, during which they are affected by persistent immune impairment, which makes them more susceptible to opportunistic infections. Prolonged exposure to ACV prophylaxis would likely make the original ACVs HSV-1 strain acquire ACV resistance due to the stronger and persistent ACV pressure.
With regard to the genetic backgrounds of ACVr HSV-1, several new findings were obtained. Regarding vTK mutations, there were 7 ACVr genotypes, including 2 with novel amino acid substitutions (G56D and L327R) in 6 patients. All of these mutations were confirmed to confer ACV resistance in a phenotype-genotype comparison and/or a functional molecular assay. Two different vTK mutants were independently isolated at different time points in patient number 206. There are 2 previous reports that describe similar findings: the emergence of various ACVr HSV-1 mutants in a short period in an HSCT patient [31] and the latent existence of minor populations of multiple ACVr HSV-1 TK variants in autopsied trigeminal ganglia samples [32] . The severe impairment of host immunity and pressure from antiviral drugs can result in the selection of minor ACVr HSV-1 populations within a single HSV-1 quasi-species pool.
DNA-pol mutations of A605V, S724N, and A719V, which had already been reported to confer ACV resistance [19] , were detected in the clinical setting of this study. One novel mutation in the DNA-pol-I890M mutation was shown to confer ACV resistance for the first time because HSV-1 with the the DNApol-I890M mutation was less sensitive than HSV-1 without this mutation (Table 4) . Aside from this residue, mutations in every amino acid from 885 to 892 have been reported to cause ACV resistance [11] , which suggests the importance of this region.
Viral thymidine kinase-associated ACVr was isolated from patient number 116 before the HSCT and many times thereafter (Table 4) . Although the patient was administered FOS for the treatment of suspected cytomegalovirus (CMV) disease (data not shown), the efficacy of FOS administration in controlling ACVr but FOS-sensitive HSV-1 shedding was not demonstrated. DNApol-associated ACVr HSV-1 was isolated from patient number 221 and patient number 227 continuously for a relatively longer period of time (Table 4) . These 2 patients were also treated with FOS for CMV disease during the HSCT course (data not shown). The ACVr HSV-1 isolated from these 2 patients was resistant not only to ACV but also to FOS. DNA-pol-associated ACVr HSV-1 was also isolated from patient number 264 in the later phase of the course (Table 4 ). This patient was also administered with FOS and GCV for the treatment of CMV disease during the HSCT course (data not shown). The efficacy of administration of these antiviral agents in reduction of ACVr HSV-1 shedding was The differences in the nucleotide sequences of each isolate's vTK and DNA-pol genes from those of the reference TAS are shown. The accession nos. of the nucleotide sequences of the reference TAS's vTK and DNA-pol genes are AB047358.1 and AB070847. All the isolates' sensitivities to antiviral drugs, including ACV, were determined simultaneously using the same reagents of the same lots. The words written in bold face indicate the data associated with the drug-resistance.
Abbreviations: FOS, foscarnet; GCV, ganciclovir; IC 50 , 50% inhibitory concentration; ND, not determined.
a indicates there that the nucleotide sequence of the isolate did not differ from the reference HSV-1 TAS.
b G del. Nts 615-9 indicates a single guanosine (G) deletion within the 5-homopolymer stretch of G.
c C del. Nts 1061-4 indicates a single cytosine (C) deletion within the 4-homopolymer stretch of C. Table 4 . Continued not evaluated. The association between ACVr HSV-1 shedding reduction and prognosis should be addressed. Notably, the proportion of patients with DNA-pol-associated ACVr HSV-1 shedding was higher in this study than in previous studies [4, 10, 33] . Consistent with previous reports, most of the DNA-pol-associated ACVr HSV-1 strains were cross-resistant to FOS [19, 34, 35] . Interestingly, most of the DNA-pol-associated ACVr HSV-1 isolates maintained sensitivity to or showed even higher sensitivity to GCV, as reported previously [19] .
This study is associated with some limitations. It is possible that the study involved bias because the samples were collected at a single center and because the number of ACVr HSV-1 shedding patients identified was relatively small. Differences between our study site and other hematological centers in factors such as the patient population and management policies might have affected the results. A prospective, multicenter surveillance study of ACVr HSV-1 in HSCT patients would be needed to reach more definitive conclusions about the clinical significance and the genetic background of ACVr HSV-1.
In conclusion, HSV-1, including both ACVs and ACVr HSV-1, shedding was associated with poorer outcomes in HSCT patients, even if HSV disease did not always occur. Patients with relapsed malignancies were at especially high risk for the emergence of ACVr HSV-1. The emergence of ACVr HSV-1 in HSCT patients partially reflects the severity of the underlying disease condition and the degree of immune impairment. The proportion of patients with DNA-pol-associated ACVr HSV-1 shedding was higher in this study than in previous reports. (3,310 words).
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